Davide Rosiello, CEO and co-founder. After a twenty years experience in the commercialization of coagulation factors and drugs for coagulopathies, in 2013 he founded BIOVIIIx, a biotechnology and pharmaceutical company active in the field of coagulopathies and rare diseases, with a particular focus on haemophilia. The company has grown very quickly, passing from 2 to 22 employees in five years, and in 2018 has been enriched with its own research laboratories.
BIOVIIIx started immediately to invest in R&D following two main strategies. The first, based on collaborations and partnerships with European and Italian research institutions, has led to the filing of 4 patents. The second is based on promoting the foundation of four start ups: 3P Sense LTD based in London, focused on the development of new diagnostic devices; Oncovix and ANBITION based in Naples, dedicated to the development of new pharmacological products and technologies in the field of oncology and angiogenic diseases; IT Health Fusion, also based in Naples, that supports hospitals, universities and research centres with technological equipment, such as cleanrooms and onco-tools, and provides health logistics solutions.